These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16514305)

  • 1. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
    Smit C; Geskus R; Walker S; Sabin C; Coutinho R; Porter K; Prins M;
    AIDS; 2006 Mar; 20(5):741-9. PubMed ID: 16514305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
    Krentz HB; Kliewer G; Gill MJ
    HIV Med; 2005 Mar; 6(2):99-106. PubMed ID: 15807715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.
    Prins M; Sabin CA; Lee CA; Devereux H; Coutinho RA
    AIDS; 2000 Aug; 14(12):1829-37. PubMed ID: 10985321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
    Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
    HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
    Mzileni MO; Longo-Mbenza B; Chephe TJ
    Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do HIV disease progression and HAART response vary among injecting drug users in Europe?
    van Asten L; Zangerle R; Hernández Aguado I; Boufassa F; Broers B; Brettle RP; Roy Robertson J; McMenamin J; Coutinho RA; Prins M
    Eur J Epidemiol; 2005; 20(9):795-804. PubMed ID: 16170664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
    Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
    AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
    Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
    Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.
    Smit C; van den Berg C; Geskus R; Berkhout B; Coutinho R; Prins M
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):221-5. PubMed ID: 18223361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
    Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
    Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
    Brady MT; Oleske JM; Williams PL; Elgie C; Mofenson LM; Dankner WM; Van Dyke RB;
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):86-94. PubMed ID: 20035164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
    Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
    Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.